Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.

Dragana M JovanovicMartina ŠterclováNesrin MogulkocKatarzyna LewandowskaVeronika MüllerMarta HájkováMichael StudnickaJasna Tekavec-TrkanjecSimona LittnerováMartina Koziar Vasakovanull null

Published in: Respiratory research (2022)

The majority of patients with IPF demonstrate comorbidities, and many have comorbidity-related deaths. Increasing numbers of comorbidities are associated with worse survival; and this pattern is also present in patients receiving antifibrotic therapy.

Keyphrases

idiopathic pulmonary fibrosis
interstitial lung disease
free survival
risk factors
stem cells
systemic sclerosis
cell therapy